FDA Panel to Debate Compounded Peptides as Safer Alternative to Gray-Market Products

FDA advisers will evaluate whether allowing compounding pharmacies to produce largely unproven peptides presents a safer option compared to unregulated gray-market versions currently available to consumers. This advisory panel meeting represents a significant moment in the regulatory debate surrounding peptide therapies, which have gained popularity despite limited clinical evidence. Compounding pharmacies, which create customized medications, could provide better quality control and oversight than black-market sources. The discussion highlights the challenge of balancing patient access to emerging treatments with safety concerns and the need for proper clinical validation. The outcome could reshape how peptide products are regulated and distributed in the United States.